Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D0F3NH
|
||||
Former ID |
DIB012779
|
||||
Drug Name |
Balaglitazone
|
||||
Synonyms |
DRF-2593; NN-2344; DRF-2593-307; NNC-61-0645
|
||||
Drug Type |
Small molecular drug
|
||||
Indication | Type 1 diabetes [ICD9: 250; ICD10:E10] | Phase 3 | [522085] | ||
Company |
Dr Reddy's Research Foundation
|
||||
Structure |
Download2D MOL |
||||
Formula |
C20H17N3O4S
|
||||
Canonical SMILES |
n1(c(=O)c2c(nc1COc1ccc(CC3C(=O)NC(=O)S3)cc1)cccc2)C
|
||||
CAS Number |
CAS 199113-98-9
|
||||
PubChem Compound ID | |||||
Target and Pathway | |||||
Target(s) | Peroxisome proliferator activated receptor gamma | Target Info | Modulator | ||
PANTHER Pathway | CCKR signaling map ST | ||||
WikiPathways | Wnt Signaling Pathway Netpath | ||||
Nuclear Receptors in Lipid Metabolism and Toxicity | |||||
Differentiation of white and brown adipocyte | |||||
Regulation of Lipid Metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha) | |||||
Transcriptional Regulation of White Adipocyte Differentiation | |||||
Adipogenesis | |||||
SREBP signalling | |||||
Nuclear Receptors | |||||
References |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.